Key Insights

Highlights

Success Rate

70% trial completion

Published Results

17 trials with published results (21%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

20.0%

16 terminated out of 80 trials

Success Rate

69.8%

-16.7% vs benchmark

Late-Stage Pipeline

11%

9 trials in Phase 3/4

Results Transparency

46%

17 of 37 completed with results

Key Signals

17 with results70% success16 terminated

Data Visualizations

Phase Distribution

56Total
Not Applicable (17)
P 1 (12)
P 2 (18)
P 3 (5)
P 4 (4)

Trial Status

Completed37
Terminated16
Unknown11
Recruiting10
Withdrawn3
Active Not Recruiting2

Trial Success Rate

69.8%

Benchmark: 86.5%

Based on 37 completed trials

Clinical Trials (80)

Showing 20 of 20 trials
NCT00033137RecruitingPrimary

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

NCT03091192Phase 3Active Not Recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT06126159Not ApplicableActive Not RecruitingPrimary

MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers

NCT02439008Not ApplicableTerminated

Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response

NCT07225114Phase 2Recruiting

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

NCT06680089Phase 2Recruiting

CD70-targeted immunoPET Imaging of Kidney Cancer

NCT05917106Recruiting

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

NCT06676527Recruiting

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

NCT02404584CompletedPrimary

The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer

NCT05432232Not ApplicableCompleted

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy

NCT05935748Phase 2Terminated

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NCT05119335Phase 1Terminated

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT03160274Recruiting

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

NCT01218854Phase 1Completed

A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy

NCT04513522Phase 4CompletedPrimary

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

NCT05944237Phase 1Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

NCT06536439Not ApplicableRecruiting

Planning Operative Strategy Using a Digital Renal Artery Clamping Tool

NCT05184504CompletedPrimary

Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American

NCT06715878Not ApplicableRecruitingPrimary

Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage

NCT05363072Completed

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Scroll to load more

Research Network

Activity Timeline